4/A//SEC Filing
Leupin Nicolas 4/A
Accession 0001562180-25-001913
CIK 0001645113other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 9:26 PM ET
Size
12.8 KB
Accession
0001562180-25-001913
Insider Transaction Report
Form 4/AAmended
NovoCure LtdNVCR
Leupin Nicolas
Chief Medical Officer
Transactions
- Sale
Ordinary Shares
2025-02-27$20.55/sh−161$3,308→ 50,133 total - Sale
Ordinary Shares
2025-02-27$19.92/sh−830$16,535→ 50,294 total
Footnotes (3)
- [F1]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F2]On February 27, 2025, the reporting person sold 830 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- [F3]On the transaction date, the reporting person sold 161 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
Issuer
NovoCure Ltd
CIK 0001645113
Entity typeother
Related Parties
1- filerCIK 0002007766
Filing Metadata
- Form type
- 4/A
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 9:26 PM ET
- Size
- 12.8 KB